Tocilizumab, an interleukin-6 receptor (IL-6R) antagonist, has been investigated as a potential therapy for acute coronary syndrome (ACS), particularly acute myocardial infarction (AMI), due to its anti-inflammatory properties and its ability to modulate the inflammatory response that contributes to myocardial injury and adverse outcomes. Here, IL6R is linked to acute myocardial infarction.